Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on
increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against …

Prostate cancer that is resistant to castration has been a prominent health challenge in the
lives of men, particularly older men. This study looks at the spectroscopic properties, density …

Increasing evidence suggests that tumor development requires not only oncogene/tumor
suppressor mutations to drive the growth, survival, and metastasis but also metabolic …

Chemokines and their cognate receptors comprise an intricate signaling network that
becomes high-jacked by cancer cells for uncontrollable tumor growth and dissemination …

Tumor-secreted exosomes have a wide range of effects on the growth, metastasis, and drug
resistance of cancer cells. However, whether and how the molecular mechanisms that …

Prostate cancer is featured by its heterogeneous nature, which indicates a different
prognosis. Castration-resistant prostate cancer (CRPC) is a hallmark of the treatment …

Metastatic castration-resistant prostate cancer (mCRPC) remains a deadly disease due to a
lack of efficacious treatments. The reprogramming of cancer metabolism toward elevated …

Conventional treatment of prostate cancer (PCa) uses androgen-deprivation therapy (ADT)
to inhibit androgen receptor (AR) signaling-driven tumor progression. ADT-induced PCa …

Lethal prostate cancer (PCa) is characterized by the presence of metastases and
development of resistance to therapies. Metastases form in a multi-step process enabled by …

Castration-resistant prostate cancer (CRPC) is an incurable form of prostate cancer (PCa),
with DNMT1 and G9a being reported as overexpressed, rendering them highly attractive …